In this trial of >18K patients with ACS, they were randomized to ticagrelor (an oral reversible direct inhibitor of adenosine diphosphate) or clopidogrel. At 1 year, rates of MI/CVA/Vascular death were lower in the ticagrelor group (10%) than the clopidogrel group (12%) with no difference in overall bleeding (abstract). Ticagrelor is superior to clopidogrel in reducing events post-ACS, and is pending FDA approval.
“Membership in the American Academy of Professional Coders has risen to more than 170,000 today from roughly 70,000 in 2008.” “The AMA owns the copyright to CPT, the code used by doctors. It publishes coding books and dictionaries. It also creates new codes when doctors want to charge for a new procedure. It levies a […]
Yeah, I know the headline drew you in. I sleuthed ya—but I have a reason. A study out in BMJ today, and its timing is uncanny given the immigration ban we are now experiencing. First, to declare my priors. I will take an IMG to work by my side any day of the week. You need […]
The Centers for Medicare & Medicaid Services (CMS) has not updated its rules (“conditions for participation”) for nursing homes in twenty-five years. Late last year they finally did. Many of the changes will have an impact on the daily lives of NH residents but are far removed from hospital medicine. Think a resident’s ability to […]